Rocket Pharmaceuticals, Inc. (NASDAQ:RCKTW – Get Free Report) saw a significant drop in short interest during the month of January. As of January 15th, there was short interest totaling 1,927 shares, a drop of 56.2% from the December 31st total of 4,399 shares. Based on an average daily trading volume, of 11,509 shares, the short-interest ratio is currently 0.2 days. Based on an average daily trading volume, of 11,509 shares, the short-interest ratio is currently 0.2 days.
Rocket Pharmaceuticals Stock Up 1.9%
Rocket Pharmaceuticals stock traded up $0.00 during trading hours on Friday, hitting $0.02. The company had a trading volume of 10,000 shares, compared to its average volume of 10,347. Rocket Pharmaceuticals has a one year low of $0.01 and a one year high of $0.09. The firm has a 50-day moving average of $0.02 and a 200 day moving average of $0.03.
Rocket Pharmaceuticals Company Profile
Rocket Pharmaceuticals, Inc is a clinical-stage biotechnology company focused on developing and commercializing novel, life-transforming gene therapies for rare pediatric diseases. The company’s research and development activities center on inherited genetic disorders, leveraging both lentiviral and adeno-associated virus (AAV) platforms to deliver corrective genes. Rocket’s lead programs include treatments for conditions such as Fanconi anemia, leukocyte adhesion deficiency-I (LAD-I), Danon disease and mucopolysaccharidosis type IIIA (MPS IIIA), each of which represents a high unmet medical need in the pediatric population.
Founded in 2015, Rocket Pharmaceuticals went public in 2018 and trades on the Nasdaq under the ticker symbol RCKTW.
Further Reading
- Five stocks we like better than Rocket Pharmaceuticals
- What a Former CIA Agent Knows About the Coming Collapse
- ALERT: Drop these 5 stocks before the market opens tomorrow!
- Buy This Stock at 9:30 AM on MONDAY!
- A month before the crash
- New Banking Law #1582 Could Unlock $21 Trillion for Americans
Receive News & Ratings for Rocket Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rocket Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
